Halozyme Therapeutics Aktie
66,74
EUR
+1,96
EUR
+3,03
%
79,45
USD
+2,51
USD
+3,26
%
Werbung
Halozyme Therapeutics Aktie Analyse
| 15.11.24 | Halozyme Therapeutics Neutral | JP Morgan Chase & Co. | |
| 27.09.12 | Halozyme Therapeutics neutral | UBS AG | |
| 12.08.08 | Halozyme Therapeutics hold | Brean Murray, Carret & Co., LLC |
Werbung
Werbung